Asia-Pacific’s medical devices industry saw a drop of 6.67% in deal activity during August 2022, when compared with the last 12-month average, led by Bain Capital’s $3.12bn private equity deal with Evident, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 42 medical devices industry deals worth $3.4bn were announced for the region in August 2022, against the 12-month average of 45 deals.
Of all the deal types, venture financing saw most activity in August 2022 with 37 transactions, representing an 88.1% share for the region.
In second place was M&A with four deals, followed by private equity deals with one transactions, respectively capturing a 9.5% and 2.4% share of the overall deal activity for the month.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
In terms of value of deals, private equity was the leading category in Asia-Pacific’s medical devices industry with $3.12bn, while venture financing and M&A deals totalled $212.98m and $15.5m, respectively.
Asia-Pacific medical devices industry deals in August 2022: Top deals
The top five medical devices deals accounted for 97% of the overall value during August 2022.
The combined value of the top five medical devices deals stood at $3.25bn, against the overall value of $3.4bn recorded for the month.
The top five medical devices industry deals of August 2022 tracked by GlobalData were:
1) Bain Capital’s $3.12bn private equity deal with Evident
2) The $52.57m venture financing of CureApp by The Carlyle Group
3) China State-owned Enterprise Structural Adjustment Fund Phase II and Wuxi Guolian Guokang Health Industry Investment Center’s $29.58m venture financing deal with Cygnus Biosciences (Beijing)
4) The $29.19m venture financing of Prismlab China by BASF Venture Capital (Shanghai), Jinyu Bogor Investment Management Co. and Qiming Venture Partners
5) Paragon Care Group Australia’s $15.5m acquisition deal with Specialist Medical Supplies